Aktiia OPBM Single-center Prospective Observational Study Against Double Auscultation

Blood Pressure Clinical Trial

Official title:

Single-center Prospective Observational Study to Validate the Performance of the Aktiia Optical Blood Pressure Monitoring (OBPM) Device at the Wrist Against Double Auscultation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04027777
• Other study ID #: OBPM_Ambulatory2019
• Status: Recruiting
• Phase: N/A
• Start date: August 6, 2019
• Est. completion date: December 31, 2024

Study information

• Verified date: January 2024
• Source: Aktiia SA
• Contact: Josep Sola, PhD
• Phone: +41797689800
• Email: josep[@]aktiia.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Single-centre prospective observational study to validate the performance of the Aktiia SA optical blood pressure monitoring (OBPM) device at the wrist against blood pressure measurements obtained by double auscultation at the upper arm during four weeks

Description:

According to the World Health Organization, by 2025 hypertension will affect 1.5 billion adults worldwide. Half of the adult population is not diagnosed, and half of the treated population is not at the defined target of BP. Widespread use of out of office BP measurement is one of the proposed strategies to fight against hypertension worldwide.

The current Ambulatory Blood Pressure Monitoring or Home Blood Pressure Monitoring are performed with a cuff placed around the arm. This 110-year-old technology is not only uncomfortable for the patient but can also result in a number of overestimated readings due to the stress induced while inflating the cuff.

Aktiia S.A. has developed an intermittent automated non-invasive cuffless blood pressure monitor determining over a series of cardiac cycles the values of the systolic blood pressure, the diastolic blood pressure and the heart rate. This miniature device is comfortably positioned with a bracelet on a user's wrist. The optical sensors integrated within the device exploit the principle of reflection photoplethysmography (PPG) to capture the user's skin pulsatility (change of arterial diameter occurring at each heartbeat). Aktiia OBPM algorithms are further applied to the recorded PPG signal to determine user's blood pressure and heart rate.

Because the measurement relies on optical sensors, and not on pneumatic cuffs, Aktiia OBPM device provides an increased overall comfort to the patient throughout the monitoring, does not induce sleep arousal during the night measurements and decreases the false positive readings induced by the stress associated with the cuff inflation. Aktiia OBPM device is intended to be used in the long term, as compared to one-day or one-week use of Ambulatory Blood Pressure Monitors.

This study over several visits has been designed to assess both the accuracy and the stability of the Aktiia OBPM. The automaticity of the measurement when performed in different body positions and upon aerobic exercise was also evaluated.

By demonstrating both the accuracy and the stability of the measurements that can be performed in different body positions with a comfortable and miniature Aktiia OBPM device, Aktiia SA aims to make one step further in facilitating blood pressure measurement and monitoring in the out-of-clinic scenarios and integrating blood pressure monitoring into user's daily life. The diagnosis and treatment of hypertension in ambulatory settings is expected to largely benefit from these advancements

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 185
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 85 Years

Eligibility

ARM1

Inclusion Criteria:

• Adult subjects (aged between 21 and 65 years old)

• Subjects fluent in written and spoken French

• Subjects agreeing to attend the totality of 4 visits

• Subjects that have signed the informed consent form

Exclusion Criteria:

• Subjects with tachycardia (heart rate at rest > 120bpm)

• Subjects with atrial fibrillation

• Subjects with diabetes

• Subjects with renal dysfunctions (eGFR < 60mL/min/1.73 m2)

• Subjects with hyper-/hypothyroidism

• Subjects with pheochromocytoma

• Subjects with Raynaud's disease

• Subjects with trembling and shivering

• Subjects with interarm systolic difference > 15 mmHg

• Subjects with interarm diastolic difference > 10 mmHg

• Subjects with arm paralysis

• Women in known pregnancy

• Subjects with an arteriovenous fistula

• Subjects with arm amputations

• Subjects with the upper arm circumference > 64 cm

• Subjects with the wrist circumference > 22 cm (limitation due Aktiia.bracelet-P0 size)

• Subjects with the central phalanx of the middle finger circumference > 71 mm or < 43 mm

• Subjects with the exfoliative skin diseases (limitation due to participant discomfort)

• Subjects with lymphoedema (limitation due to participant discomfort)

ARM2

Inclusion Criteria:

• Adult subjects (aged between 21 and 65 years old)

• Subjects fluent in written and spoken French

• Subjects agreeing to attend the totality of 4 visits

• Subjects that have signed the informed consent form

Exclusion Criteria:

• Subjects with tachycardia (heart rate at rest > 120bpm)

• Subjects with atrial fibrillation

• Subjects with hyper-/hypothyroidism

• Subjects with pheochromocytoma

• Subjects with Raynaud's disease

• Subjects with trembling and shivering

• Subjects with interarm systolic difference > 15 mmHg

• Subjects with interarm diastolic difference > 10 mmHg

• Subjects with arm paralysis

• Women in known pregnancy

• Subjects with an arteriovenous fistula

• Subjects with arm amputations

• Subjects with the upper arm circumference > 64 cm

• Subjects with the wrist circumference > 22 cm (limitation due Aktiia.bracelet-P0 size)

• Subjects with the central phalanx of the middle finger circumference > 71 mm or < 43 mm

• Subjects with the exfoliative skin diseases (limitation due to participant discomfort)

• Subjects with lymphoedema (limitation due to participant discomfort)

ARM3

Inclusion Criteria:

• Adult subjects (aged between 65 and 85 years old)

• Subjects fluent in written and spoken French

• Subjects agreeing to attend the totality of 4 visits

• Subjects that have signed the informed consent form

Exclusion Criteria:

• Subjects with tachycardia (heart rate at rest > 120bpm)

• Subjects with atrial fibrillation

• Subjects with diabetes

• Subjects with renal dysfunctions (eGFR < 60mL/min/1.73 m2)

• Subjects with hyper-/hypothyroidism

• Subjects with pheochromocytoma

• Subjects with Raynaud's disease

• Subjects with trembling and shivering

• Subjects with interarm systolic difference > 15 mmHg

• Subjects with interarm diastolic difference > 10 mmHg

• Subjects with arm paralysis

• Women in known pregnancy

• Subjects with an arteriovenous fistula

• Subjects with arm amputations

• Subjects with the upper arm circumference > 64 cm

• Subjects with the wrist circumference > 22 cm (limitation due Aktiia.bracelet-P0 size)

• Subjects with the central phalanx of the middle finger circumference > 71 mm or < 43 mm

• Subjects with the exfoliative skin diseases (limitation due to participant discomfort)

• Subjects with lymphoedema (limitation due to participant discomfort)

Related Conditions & MeSH terms

• Blood Pressure

Intervention

Device:
• Aktiia.product-P0
The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.

Locations

Country	Name	City	State
Switzerland	University of Lausanne Hospitals	Lausanne

Sponsors (2)

Lead Sponsor	Collaborator
Aktiia SA	University of Lausanne Hospitals

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood Pressure absolute Mean Error	The absolute value of the mean of the differences between Reference and Aktiia.product-P0 blood pressure determinations	Up to four weeks
Primary	Blood Pressure standard Deviation of the Error	The standard deviation of the differences between Reference and Aktiia.product-P0 determinations	Up to four weeks
Secondary	Heart Rate root-mean-square error	The root-mean-square difference between the Aktiia.product-P0 heart rate determinations and the Reference method	Up to four weeks

External Links

•   Sponsor website